View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAptahem 과거 순이익 실적과거 기준 점검 0/6Aptahem은 연평균 33.9%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 35.6%의 비율로 증가했습니다.핵심 정보33.94%순이익 성장률68.17%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률35.64%자기자본이익률-9.63%순이익률-251.07%다음 순이익 업데이트28 May 2026최근 과거 실적 업데이트공시 • Apr 29Aptahem AB (publ) to Report Q1, 2026 Results on May 28, 2026Aptahem AB (publ) announced that they will report Q1, 2026 results on May 28, 2026Reported Earnings • Nov 30Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr1.39m (loss widened 17% from 3Q 2024).공시 • Oct 23Aptahem AB (publ) to Report Q3, 2025 Results on Nov 28, 2025Aptahem AB (publ) announced that they will report Q3, 2025 results on Nov 28, 2025Reported Earnings • Aug 31Second quarter 2025 earnings releasedSecond quarter 2025 results: Net loss: kr1.36m (loss narrowed 49% from 2Q 2024).공시 • Jul 29Aptahem AB (publ) to Report Q2, 2025 Results on Aug 28, 2025Aptahem AB (publ) announced that they will report Q2, 2025 results on Aug 28, 2025Reported Earnings • May 23First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: kr2.01m (loss narrowed 26% from 1Q 2024).모든 업데이트 보기Recent updates공시 • Apr 29Aptahem AB (publ) to Report Q1, 2026 Results on May 28, 2026Aptahem AB (publ) announced that they will report Q1, 2026 results on May 28, 2026공시 • Mar 27Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 13.841627 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 13.841627 million. Security Name: Shares Security Type: Common Stock Securities Offered: 20,972,162 Price\Range: SEK 0.66 Transaction Features: Rights OfferingBoard Change • Mar 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 30Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr1.39m (loss widened 17% from 3Q 2024).공시 • Oct 23Aptahem AB (publ) to Report Q3, 2025 Results on Nov 28, 2025Aptahem AB (publ) announced that they will report Q3, 2025 results on Nov 28, 2025공시 • Sep 02Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 24.861 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 24.861 million. Security Name: Shares Security Type: Common Stock Securities Offered: 15,346,296 Price\Range: SEK 1.62 Transaction Features: Rights OfferingNew Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (205% increase in shares outstanding). Revenue is less than US$1m (kr3.7m revenue, or US$388k). Market cap is less than US$10m (€2.73m market cap, or US$3.19m).Reported Earnings • Aug 31Second quarter 2025 earnings releasedSecond quarter 2025 results: Net loss: kr1.36m (loss narrowed 49% from 2Q 2024).공시 • Aug 28Aptahem AB (publ) Announces Submission of Application for FDA's Commissioner's National Priority Voucher Pilot ProgramAptahem AB (publ) announced that the company has submitted an application for participation in the U.S. Food and Drug Administration's (FDA) Commissioner's National Priority Voucher (CNPV) Pilot Program - "Accelerated Drug Review for Companies Supporting U.S. National Interests." The application is made as a next step after Aptahem's previous application to FDA PreCheck on August 13, 2025. It complements the company's application to FDA PreCheck and strengthens the U.S.-focused regulatory strategy. CNPV is a new pilot program where the FDA, for a limited number of companies, can award a "voucher" that provides significantly shortened regulatory review processing times - from normally around 10-12 months to around 1-2 months - while maintaining applicable safety and efficacy requirements. The selection is directed at development programs that are in line with US national health priorities (e.g., high unmet medical needs, innovation level, crisis management, onshoring, and supply chain robustness). In the first round of the pilot year, a maximum of five participants are intended to be selected. To qualify, it is required, among other things, that the manufacturing part and proposed labeling are submitted at least 60 days before the final application and that the company can maintain a close dialogue with the FDA's cross-functional review team.공시 • Aug 21Aptahem Files Provisional Patent Application in Usa for New Indications for Apta-1Aptahem AB (publ) announced that the company has received patent pending status through a provisional patent application in the USA. The application aims to protect the company's lead RNA aptamer Apta-1 in new indication areas, based on detailed evaluation of data generated from previous studies with Apta-1. These new insights are based on the detailed evaluation of data generated from Apta-1 by the Company's Co-Founder and CSO Dr. Luiza Jedlina. Dr. Jedlina has identified entirely new indications for the Company's lead RNA aptamer, Apta-1. These discoveries are now protected by a provisional patent application in the United States, further strengthening Apta-1's position as a first-in-class, innovative therapy option. Some of the identified indications include: Neurodegenerative diseases: Apta-1 blocks interactions of Amyloid-b and tau, with the potential to slow progression in Alzheimer's, Parkinson's, frontotemporal dementia, and Huntington's disease. Viral infections: Effective against HSV, CMV, Dengue, Zika, SARS-CoV-2, MERS, HIV, and HPV by preventing viral cell entry. Cancer and metastasis: Inhibits growth factors, slowing angiogenesis and tumor cell spread in aggressive cancers such as breast cancer, melanoma, and glioblastoma. Fibrotic diseases and infectious conditions: interesting indications for idiopathic pulmonary fibrosis, liver and kidney fibrosis, as well as in certain infectious diseases. Dr. Jedlina's evaluation of the study results shows that Apta-1 has the potential to stop disease-driving mechanisms at multiple levels - from protein aggregation and pathogen entry to tissue damage and fibrosis - making Apta-1 a potential game-changer in these indication areas.공시 • Aug 16Aptahem AB (publ) Applies to FDA Precheck Program - Strategic Step Toward Faster, Higher-Quality Drug ManufacturingAptahem AB (publ) is strengthening its position as a leader in RNA-based therapeutics by applying to the FDA PreCheck Program, the agency's new initiative to accelerate and streamline inspections of drug manufacturing. The program is reserved for companies with a proven track record of high-quality, GMP-compliant operations, offering prioritized inspections and regulatory transparency. For Aptahem, participation means:Faster regulatory pathway for production of Apta-1, its breakthrough RNA aptamer for severe inflammatory conditions. Enhanced confidence from partners and investors, demonstrating the company's commitment to top-tier quality and innovation. Clear quality milestone reducing risks and timelines, supporting future clinical and commercial expansion.공시 • Jul 29Aptahem AB (publ) to Report Q2, 2025 Results on Aug 28, 2025Aptahem AB (publ) announced that they will report Q2, 2025 results on Aug 28, 2025Reported Earnings • May 23First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: kr2.01m (loss narrowed 26% from 1Q 2024).공시 • May 08Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 9.7 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 9.7 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Rights Offering공시 • Mar 14Aptahem AB (publ) Presents Plan for Upcoming Patient StudyAptahem AB (publ) announced a summary for the upcoming clinical phase 2 study of the drug candidate Apta-1. The study will be performed as an open, single arm phase 2 study to evaluate the efficacy and safety of Apta-1, an innovative immunomodulatory and antithrombotic drug candidate, in patients with acute urogenital andrenal conditions. The study will be perform as a Proof-of-Concept study in adult patients diagnosed with various types of acute urogenital disorders including acute kidney disorders. Within these disorders, there are several indications with orphan status, an area where Aptahem sees great potential for Apta-1 based on its unique therapeutic profile. To maximize the opportunities to create value from Apta-1's broad treatment potential, the study is planned to be conducted as a "basket trial", where several acute medical conditions within the relevant patient group are investigated in parallel. The study's primary objectives include biomarkers for hematology, organ function, inflammation, tissue degradation, and reduction of pathogens such as viruses and bacteria. The goal is to demonstrate both therapeutic efficacy and safety. More detailed information about the study will be published in the near future.Reported Earnings • Feb 20Full year 2024 earnings released: kr0.69 loss per share (vs kr5.79 loss in FY 2023)Full year 2024 results: kr0.69 loss per share (improved from kr5.79 loss in FY 2023). Net loss: kr8.57m (loss narrowed 23% from FY 2023).공시 • Feb 18+ 1 more updateAptahem AB (publ) to Report Q1, 2025 Results on May 28, 2025Aptahem AB (publ) announced that they will report Q1, 2025 results on May 28, 2025공시 • Jan 16Aptahem AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025Aptahem AB (publ) announced that they will report fiscal year 2024 results on Feb 14, 2025Reported Earnings • Dec 03Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr1.18m (loss narrowed 26% from 3Q 2023).Board Change • Dec 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Oct 31Aptahem AB (publ) to Report Q3, 2024 Results on Nov 29, 2024Aptahem AB (publ) announced that they will report Q3, 2024 results on Nov 29, 2024공시 • Sep 02Aptahem AB (Publ) Announces Completion of Double-Blind Randomised Placebo-Controlled Phase 1 StudyAptahem AB (publ) announced that the completed double-blind randomised placebo-controlled phase 1 study in healthy volunteers also showed indications of drug efficacy. Aptahem has summarised and concluded all additional analyses taking into account the recently completed phase 1 study. At dosing, interesting immunological marker responses were noted in the subjects, prompting further analyses and evaluation of safety and mechanism of action. The analyses revealed that one individual had elevated inflammatory values prior to dosing. In this case, Apta-1 dosing was associated with rapid reduction of inflammatory parameters, with the first signs of normalisation seen already within 4 hours of dosing and further reduction at 6 hours to be completely reduced at the next measurement point at 24 hours. This suggests that Apta-1 could counteract inflammatory responses in individuals with ongoing inflammation. The latter observations are consistent with preclinical data and the proposed mechanism of action showing that Apta-1 protects against acute inflammation. This has been replicated in several independent models and reinforces the belief that Apta-1 can be developed into an effective drug against life-threatening inflammatory disease. Strengthened by these findings, a confirmatory Phase 2 clinical trial in patients with acute inflammatory disease is now being planned in consultation with the company's expert advisors.Reported Earnings • Sep 01Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr2.63m (loss narrowed 3.7% from 2Q 2023).공시 • Aug 01Aptahem AB (publ) to Report Q2, 2024 Results on Aug 30, 2024Aptahem AB (publ) announced that they will report Q2, 2024 results on Aug 30, 2024Board Change • Jul 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jun 28Aptahem AB (publ) Reports the FIH Study on Apta-1 Has Been FinalizedAptahem AB (publ) announced that the report on the First in Human (FIH) study has been finalized. The final study report confirms the previous top line results. The study is now closed and reported to the authorities. The top line results previously communicated from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during the study of Apta-1 highlighted some clinical markers which are important for understanding the mechanism of action and to support upcoming patient studies. The significance of these findings are being further investigated aided by pre-clinical studies.Board Change • Jun 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Jan Nilsson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.매출 및 비용 세부 내역Aptahem가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:94V 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Dec 253-69030 Sep 252-810030 Jun 253-79031 Mar 253-811031 Dec 244-912030 Sep 2411-1020030 Jun 2412-1122031 Mar 2411-1121031 Dec 2310-1120030 Sep 233-1013030 Jun 233-1013031 Mar 233-913031 Dec 223-913030 Sep 222-1215030 Jun 221-1517031 Mar 221-1819031 Dec 210-2828030 Sep 210-3535030 Jun 210-3434031 Mar 210-3333031 Dec 200-2424030 Sep 200-1514030 Jun 200-1616031 Mar 200-1717031 Dec 190-1717030 Sep 190-181030 Jun 190-16-1031 Mar 190-214031 Dec 180-214030 Sep 180-1912030 Jun 180-1710031 Mar 180-114031 Dec 170-103030 Sep 170-104030 Jun 170-104031 Mar 170-104031 Dec 160-104030 Sep 160-107030 Jun 160-86031 Mar 160-630양질의 수익: 94V 은(는) 현재 수익성이 없습니다.이익 마진 증가: 94V는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 94V는 수익성이 없지만 지난 5년 동안 연평균 33.9%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 94V의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 94V은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(45%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 94V는 현재 수익성이 없으므로 자본 수익률이 음수(-9.63%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/02 22:15종가2026/03/19 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aptahem AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 29Aptahem AB (publ) to Report Q1, 2026 Results on May 28, 2026Aptahem AB (publ) announced that they will report Q1, 2026 results on May 28, 2026
Reported Earnings • Nov 30Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr1.39m (loss widened 17% from 3Q 2024).
공시 • Oct 23Aptahem AB (publ) to Report Q3, 2025 Results on Nov 28, 2025Aptahem AB (publ) announced that they will report Q3, 2025 results on Nov 28, 2025
Reported Earnings • Aug 31Second quarter 2025 earnings releasedSecond quarter 2025 results: Net loss: kr1.36m (loss narrowed 49% from 2Q 2024).
공시 • Jul 29Aptahem AB (publ) to Report Q2, 2025 Results on Aug 28, 2025Aptahem AB (publ) announced that they will report Q2, 2025 results on Aug 28, 2025
Reported Earnings • May 23First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: kr2.01m (loss narrowed 26% from 1Q 2024).
공시 • Apr 29Aptahem AB (publ) to Report Q1, 2026 Results on May 28, 2026Aptahem AB (publ) announced that they will report Q1, 2026 results on May 28, 2026
공시 • Mar 27Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 13.841627 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 13.841627 million. Security Name: Shares Security Type: Common Stock Securities Offered: 20,972,162 Price\Range: SEK 0.66 Transaction Features: Rights Offering
Board Change • Mar 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 30Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr1.39m (loss widened 17% from 3Q 2024).
공시 • Oct 23Aptahem AB (publ) to Report Q3, 2025 Results on Nov 28, 2025Aptahem AB (publ) announced that they will report Q3, 2025 results on Nov 28, 2025
공시 • Sep 02Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 24.861 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 24.861 million. Security Name: Shares Security Type: Common Stock Securities Offered: 15,346,296 Price\Range: SEK 1.62 Transaction Features: Rights Offering
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (205% increase in shares outstanding). Revenue is less than US$1m (kr3.7m revenue, or US$388k). Market cap is less than US$10m (€2.73m market cap, or US$3.19m).
Reported Earnings • Aug 31Second quarter 2025 earnings releasedSecond quarter 2025 results: Net loss: kr1.36m (loss narrowed 49% from 2Q 2024).
공시 • Aug 28Aptahem AB (publ) Announces Submission of Application for FDA's Commissioner's National Priority Voucher Pilot ProgramAptahem AB (publ) announced that the company has submitted an application for participation in the U.S. Food and Drug Administration's (FDA) Commissioner's National Priority Voucher (CNPV) Pilot Program - "Accelerated Drug Review for Companies Supporting U.S. National Interests." The application is made as a next step after Aptahem's previous application to FDA PreCheck on August 13, 2025. It complements the company's application to FDA PreCheck and strengthens the U.S.-focused regulatory strategy. CNPV is a new pilot program where the FDA, for a limited number of companies, can award a "voucher" that provides significantly shortened regulatory review processing times - from normally around 10-12 months to around 1-2 months - while maintaining applicable safety and efficacy requirements. The selection is directed at development programs that are in line with US national health priorities (e.g., high unmet medical needs, innovation level, crisis management, onshoring, and supply chain robustness). In the first round of the pilot year, a maximum of five participants are intended to be selected. To qualify, it is required, among other things, that the manufacturing part and proposed labeling are submitted at least 60 days before the final application and that the company can maintain a close dialogue with the FDA's cross-functional review team.
공시 • Aug 21Aptahem Files Provisional Patent Application in Usa for New Indications for Apta-1Aptahem AB (publ) announced that the company has received patent pending status through a provisional patent application in the USA. The application aims to protect the company's lead RNA aptamer Apta-1 in new indication areas, based on detailed evaluation of data generated from previous studies with Apta-1. These new insights are based on the detailed evaluation of data generated from Apta-1 by the Company's Co-Founder and CSO Dr. Luiza Jedlina. Dr. Jedlina has identified entirely new indications for the Company's lead RNA aptamer, Apta-1. These discoveries are now protected by a provisional patent application in the United States, further strengthening Apta-1's position as a first-in-class, innovative therapy option. Some of the identified indications include: Neurodegenerative diseases: Apta-1 blocks interactions of Amyloid-b and tau, with the potential to slow progression in Alzheimer's, Parkinson's, frontotemporal dementia, and Huntington's disease. Viral infections: Effective against HSV, CMV, Dengue, Zika, SARS-CoV-2, MERS, HIV, and HPV by preventing viral cell entry. Cancer and metastasis: Inhibits growth factors, slowing angiogenesis and tumor cell spread in aggressive cancers such as breast cancer, melanoma, and glioblastoma. Fibrotic diseases and infectious conditions: interesting indications for idiopathic pulmonary fibrosis, liver and kidney fibrosis, as well as in certain infectious diseases. Dr. Jedlina's evaluation of the study results shows that Apta-1 has the potential to stop disease-driving mechanisms at multiple levels - from protein aggregation and pathogen entry to tissue damage and fibrosis - making Apta-1 a potential game-changer in these indication areas.
공시 • Aug 16Aptahem AB (publ) Applies to FDA Precheck Program - Strategic Step Toward Faster, Higher-Quality Drug ManufacturingAptahem AB (publ) is strengthening its position as a leader in RNA-based therapeutics by applying to the FDA PreCheck Program, the agency's new initiative to accelerate and streamline inspections of drug manufacturing. The program is reserved for companies with a proven track record of high-quality, GMP-compliant operations, offering prioritized inspections and regulatory transparency. For Aptahem, participation means:Faster regulatory pathway for production of Apta-1, its breakthrough RNA aptamer for severe inflammatory conditions. Enhanced confidence from partners and investors, demonstrating the company's commitment to top-tier quality and innovation. Clear quality milestone reducing risks and timelines, supporting future clinical and commercial expansion.
공시 • Jul 29Aptahem AB (publ) to Report Q2, 2025 Results on Aug 28, 2025Aptahem AB (publ) announced that they will report Q2, 2025 results on Aug 28, 2025
Reported Earnings • May 23First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: kr2.01m (loss narrowed 26% from 1Q 2024).
공시 • May 08Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 9.7 million.Aptahem AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 9.7 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Rights Offering
공시 • Mar 14Aptahem AB (publ) Presents Plan for Upcoming Patient StudyAptahem AB (publ) announced a summary for the upcoming clinical phase 2 study of the drug candidate Apta-1. The study will be performed as an open, single arm phase 2 study to evaluate the efficacy and safety of Apta-1, an innovative immunomodulatory and antithrombotic drug candidate, in patients with acute urogenital andrenal conditions. The study will be perform as a Proof-of-Concept study in adult patients diagnosed with various types of acute urogenital disorders including acute kidney disorders. Within these disorders, there are several indications with orphan status, an area where Aptahem sees great potential for Apta-1 based on its unique therapeutic profile. To maximize the opportunities to create value from Apta-1's broad treatment potential, the study is planned to be conducted as a "basket trial", where several acute medical conditions within the relevant patient group are investigated in parallel. The study's primary objectives include biomarkers for hematology, organ function, inflammation, tissue degradation, and reduction of pathogens such as viruses and bacteria. The goal is to demonstrate both therapeutic efficacy and safety. More detailed information about the study will be published in the near future.
Reported Earnings • Feb 20Full year 2024 earnings released: kr0.69 loss per share (vs kr5.79 loss in FY 2023)Full year 2024 results: kr0.69 loss per share (improved from kr5.79 loss in FY 2023). Net loss: kr8.57m (loss narrowed 23% from FY 2023).
공시 • Feb 18+ 1 more updateAptahem AB (publ) to Report Q1, 2025 Results on May 28, 2025Aptahem AB (publ) announced that they will report Q1, 2025 results on May 28, 2025
공시 • Jan 16Aptahem AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025Aptahem AB (publ) announced that they will report fiscal year 2024 results on Feb 14, 2025
Reported Earnings • Dec 03Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr1.18m (loss narrowed 26% from 3Q 2023).
Board Change • Dec 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Oct 31Aptahem AB (publ) to Report Q3, 2024 Results on Nov 29, 2024Aptahem AB (publ) announced that they will report Q3, 2024 results on Nov 29, 2024
공시 • Sep 02Aptahem AB (Publ) Announces Completion of Double-Blind Randomised Placebo-Controlled Phase 1 StudyAptahem AB (publ) announced that the completed double-blind randomised placebo-controlled phase 1 study in healthy volunteers also showed indications of drug efficacy. Aptahem has summarised and concluded all additional analyses taking into account the recently completed phase 1 study. At dosing, interesting immunological marker responses were noted in the subjects, prompting further analyses and evaluation of safety and mechanism of action. The analyses revealed that one individual had elevated inflammatory values prior to dosing. In this case, Apta-1 dosing was associated with rapid reduction of inflammatory parameters, with the first signs of normalisation seen already within 4 hours of dosing and further reduction at 6 hours to be completely reduced at the next measurement point at 24 hours. This suggests that Apta-1 could counteract inflammatory responses in individuals with ongoing inflammation. The latter observations are consistent with preclinical data and the proposed mechanism of action showing that Apta-1 protects against acute inflammation. This has been replicated in several independent models and reinforces the belief that Apta-1 can be developed into an effective drug against life-threatening inflammatory disease. Strengthened by these findings, a confirmatory Phase 2 clinical trial in patients with acute inflammatory disease is now being planned in consultation with the company's expert advisors.
Reported Earnings • Sep 01Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr2.63m (loss narrowed 3.7% from 2Q 2023).
공시 • Aug 01Aptahem AB (publ) to Report Q2, 2024 Results on Aug 30, 2024Aptahem AB (publ) announced that they will report Q2, 2024 results on Aug 30, 2024
Board Change • Jul 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Co-Founder, CEO & Director Mikael Lindstam was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jun 28Aptahem AB (publ) Reports the FIH Study on Apta-1 Has Been FinalizedAptahem AB (publ) announced that the report on the First in Human (FIH) study has been finalized. The final study report confirms the previous top line results. The study is now closed and reported to the authorities. The top line results previously communicated from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during the study of Apta-1 highlighted some clinical markers which are important for understanding the mechanism of action and to support upcoming patient studies. The significance of these findings are being further investigated aided by pre-clinical studies.
Board Change • Jun 17No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Jan Nilsson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.